A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.

[1]  M. Zahurak,et al.  Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Brünner,et al.  A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. , 2005, Gynecologic oncology.

[3]  E. Eisenhauer,et al.  Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer) , 2005 .

[4]  S. Warrington,et al.  Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men. , 2004, International journal of clinical pharmacology and therapeutics.

[5]  M. Cronk,et al.  Case report of a generalized seizure related to Paclitaxel infusion. , 2004, Journal of the National Cancer Institute.

[6]  R. Kryscio,et al.  Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆ , 2003 .

[7]  D. Boyd,et al.  A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. , 2003, The American journal of pathology.

[8]  G. Rustin,et al.  CA125 response: can it replace the traditional response criteria in ovarian cancer? , 2002, The oncologist.

[9]  A. Mazar,et al.  An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. , 2002, Cancer research.

[10]  S. Memarzadeh,et al.  Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  N. Brünner,et al.  Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  H. Nielsen,et al.  Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. , 2001, Gynecologic oncology.

[13]  H. Höfler,et al.  Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  M. Pepper.  Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[15]  C. Sweep,et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.

[16]  A. Krüger,et al.  Clinical Relevance of the Plasminogen Activator Inhibitor Type1 – a Multifaceted Proteolytic Factor , 2001, Oncology Research and Treatment.

[17]  G. Rice,et al.  Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. , 2000, Gynecologic oncology.

[18]  A. Gown,et al.  A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Selman,et al.  Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. , 2000, Oncology reports.

[20]  A. Mazar,et al.  A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[22]  D. Fishman,et al.  Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment. , 1999, The Biochemical journal.

[23]  H. Nielsen,et al.  Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. , 1999, Journal of the National Cancer Institute.

[24]  H. Miyake,et al.  Elevation of serum levels of urokinase‐type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer , 1999, The Prostate.

[25]  S. Barnhill,et al.  CA 125: The past and the Future , 1998, The International journal of biological markers.

[26]  N. Brünner,et al.  The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. , 1998, Cancer research.

[27]  J. Verweij,et al.  The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  R. Bast,et al.  CA 125 for the monitoring of ovarian carcinoma during primary therapy , 1987, Obstetrics and gynecology.

[29]  J. Niloff,et al.  The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer , 1986, American journal of obstetrics and gynecology.

[30]  A. Mazar,et al.  The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis , 2004, Angiogenesis.

[31]  D. Doering,et al.  Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. , 2001, Gynecologic oncology.

[32]  M. Piccart,et al.  Use of tumour markers in monitoring the course of ovarian cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  A. Sharma,et al.  Ovarian cancer patients with high CA-125 but no symptoms--should antiangiogenic treatments be considered? , 1997, Oncology research.